The obesity market has grown exponentially over the course of just a few years, with no signs of slowing as Big Pharma and biotech contenders vie for third place behind Eli Lilly and Novo Nordisk. This year has seen its share of action, with launches of oral offerings from both leaders and multiple clinical wins…
